Clinical Trial: An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates

U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923383) titled 'An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates' on Nov. 02.

Brief Summary: This is an open-label, single group, 2-period, Phase 1, single-arm study. The primary purpose of this study is to investigate the effects of duvakitug on the pharmacokinetics of selected cytochrome P450 substrates in adult participants with moderately to severely active ulcerative colitis or Crohn's disease. Approximately 25 participants will be enrolled. The total study duration per participant will be approximately 166 days.

Study Start Date: Nov. 03

Study Type: INTERVENTIONAL

Condition: ...